These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 701018)

  • 21. Influence of DTPA therapy on long-term effects of retained monomeric plutonium: comparison with polymeric plutonium.
    Osenthal MW; Lindenbaum A
    Radiat Res; 1967 Jul; 31(3):506-21. PubMed ID: 6027890
    [No Abstract]   [Full Text] [Related]  

  • 22. Effectiveness of DTPA treatments following the injection of particulate plutonium.
    Bruenger FW; Taylor DM; Taylor GN; Lloyd RD
    Int J Radiat Biol; 1991 Nov; 60(5):803-18. PubMed ID: 1680951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of age on the efficacy of Zn-diethylenetriaminepentaacetic acid therapy for removal of Am and Pu from beagles.
    Lloyd RD; Mays CW; Jones CW; Lloyd CR; Taylor GN; Wrenn ME
    Radiat Res; 1985 Mar; 101(3):451-9. PubMed ID: 3983361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effectiveness of pentacin (DTPA) in deposition of Ce144 in lung tissue].
    Borisov VP; Korolev GK
    Med Radiol (Mosk); 1967 Feb; 12(2):79-81. PubMed ID: 5616164
    [No Abstract]   [Full Text] [Related]  

  • 25. Progress in the beagle studies at Colorado State University.
    Watters RL; Lebel JL
    Health Phys; 1972 Jun; 22(6):811-4. PubMed ID: 5084015
    [No Abstract]   [Full Text] [Related]  

  • 26. Further comparison of Ca-DTPA and Zn-DTPA for removal of 241Am from beagles.
    Lloyd RD; Taylor GN; Boseman JJ; Mays CW; Atherton DR
    Health Phys; 1977 Jul; 33(1):92-4. PubMed ID: 893109
    [No Abstract]   [Full Text] [Related]  

  • 27. The influence of DTPA on the metabolism of inhaled 239PuF4 in beagles.
    McDonald KE; Dilley JV; Sanders CL; Mahaffey JA
    Health Phys; 1979 May; 36(5):632-5. PubMed ID: 489316
    [No Abstract]   [Full Text] [Related]  

  • 28. Improved Modeling of Plutonium-DTPA Decorporation.
    Dumit S; Avtandilashvili M; Strom DJ; McComish SL; Tabatadze G; Tolmachev SY
    Radiat Res; 2019 Feb; 191(2):201-210. PubMed ID: 30566387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decorporation of plutonium by pulmonary administration of Ca-DTPA dry powder: a study in rat after lung contamination with different plutonium forms.
    Sérandour AL; Tsapis N; Gervelas C; Grillon G; Fréchou M; Deverre JR; Bénech H; Fattal E; Fritsch P; Poncy JL
    Radiat Prot Dosimetry; 2007; 127(1-4):472-6. PubMed ID: 17562654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interpretation of human urinary excretion of plutonium for cases treated with DTPA.
    Jech JJ; Andersen BV; Heid KR
    Health Phys; 1972 Jun; 22(6):787-92. PubMed ID: 5084012
    [No Abstract]   [Full Text] [Related]  

  • 31. Combined effect of DTPA and citrate on an intramuscular 239Pu deposit in rats.
    Volf V
    Health Phys; 1974 Jul; 27(1):152-3. PubMed ID: 4430623
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA IND approval for Zn-DTPA, new clinical agent for decorporation therapy of actinides.
    Lushbaugh CC; Washburn LC
    Health Phys; 1979 Mar; 36(3):472. PubMed ID: 226499
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA IND approval for Zn-DTPA, new clinical agent for decorporation therapy of actinides.
    Lushbaugh CC; Washburn LC
    J Nucl Med; 1979 Jan; 20(1):73. PubMed ID: 219167
    [No Abstract]   [Full Text] [Related]  

  • 34. Salicylic acid failed to increase the efficacy of Ca-DTPA in the decorporation of plutonium and americium.
    Jones CW; Lloyd RD; Mays CW
    Radiat Res; 1980 Oct; 84(1):149-51. PubMed ID: 7454978
    [No Abstract]   [Full Text] [Related]  

  • 35. Delivery of DTPA through Liposomes as a Good Strategy for Enhancing Plutonium Decorporation Regardless of Treatment Regimen.
    Grémy O; Miccoli L; Lelan F; Bohand S; Cherel M; Mougin-Degraef M
    Radiat Res; 2018 May; 189(5):477-489. PubMed ID: 29528770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mathematical model for estimation of plutonium in the human body from urine data influenced by DTPA therapy.
    Hall RM; Poda GA; Fleming RR; Smith JA
    Health Phys; 1978 May; 34(5):419-31. PubMed ID: 711453
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficiency of low level DTPA therapy in removing plutonium from mice.
    Smith H; Chapman IV; Marlow CG
    Nature; 1969 May; 222(5194):676. PubMed ID: 5768280
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro and in vivo assessment of plutonium speciation and decorporation in blood and target retention tissues after a systemic contamination followed by an early treatment with DTPA.
    Sérandour AL; Grémy O; Fréchou M; Renault D; Poncy JL; Fritsch P
    Radiat Res; 2008 Aug; 170(2):208-15. PubMed ID: 18666819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Zn-DTPA in removing plutonium from the human body.
    Ohlenschläger L
    Health Phys; 1976 Feb; 30(2):249-50. PubMed ID: 1245431
    [No Abstract]   [Full Text] [Related]  

  • 40. Decorporation therapy for inhaled plutonium nitrate using repeatedly and continuously administered DTPA.
    Guilmette RA; Muggenburg BA
    Int J Radiat Biol; 1993 Mar; 63(3):395-403. PubMed ID: 8095291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.